FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
Roth Capital Reiterates Neutral on Capricor Therapeutics, Raises Price Target to $10.5
Capricor Therapeutics: A Close Look Before The November 22 DMD Drug Decision
CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month
Jones Trading Upgrades Capricor Therapeutics to Buy, Announces $25 Price Target
Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
Capricor: The FDA's Objections Change My June Buy To A Sell
Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...
Capricor (CAPR) Q3 2026 Earnings Call Transcript
Capricor Therapeutics Q3 Earnings Call Highlights
CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review
Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
Capricor: Q3 Earnings Snapshot
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Capricor Therapeutics Q3 2026 Earnings Call Transcript
Capricor Therapeutics Q3 EPS $(0.73) Misses $(0.05) Estimate
CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retail’s Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel
CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.